2026 ADAI Symposium
September 18, 2026 | 9:00am-4:00pm PT
Virtual and in-person at UW Tower, Seattle
Registration opens July 2026!
In a recent survey of Washington State healthcare providers about cannabis negative effects, 70% of respondents reported seeing cases of severe abdominal pain, nausea, retching, and relentless vomiting among people reporting heavy cannabis use1.
This cluster of symptoms is now recognized as Cannabis Hyperemesis Syndrome (CHS).
As CHS becomes more visible in clinical settings, providers are left navigating care without clear understanding or guidance. At the same time, while 1 in 10 Washingtonians who consumed cannabis in the last year report vomiting and nausea due to their cannabis use2, many people remain skeptical that the condition exists at all, creating challenges for treatment, prevention and health education.
To better understand these dynamics, we are making CHS the focus of this year’s ADAI Symposium.
Join us on September 18, 2026, to learn more about:
- CHS prevalence among adolescents and adults in U.S. emergency departments
- CHS in Washington State
- CHS as a contested disease and implications for health communication
- CHS presentation, treatment, and management across settings
- Policy recommendations to prevent CHS increase
- Improving care for individuals with CHS
Registration opens in July 2026!
References
- Carlini BH, Kellum LB, Garrett SB, & Williams JR. (2026). Cannabis-related problems, adverse events, clinical experiences and barriers to intervening: Perspectives of health care providers in Washington State [advance online publication]. Substance Use & Addiction Journal. doi: 10.1177/29767342261426116
- Carlini BH, Williams JR, Garrett SB, & Hammond D. (2026). People with psychotic disorders are the most vulnerable to cannabis adverse health outcomes: a study in WA State, SA [advance online publication]. Community Mental Health Journal. doi:10.1007/s10597-025-01579-1
